• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

A Worldwide Public Partnership Makes Available a New, Once-a-Day Fixed-Dose Combination against Malaria

Rio de Janeiro, Brazil — 17 Apr 2008
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

An innovative partnership between the Brazilian public pharmaceutical company, Farmanguinhos/Fiocruz, and the non-profit drug development organization, Drugs for Neglected Diseases initiative (DNDi), announced today that ASMQ, the new fixed-dose combination of artesunate (AS) and mefloquine (MQ), is now registered and available in Brazil.
[Português] [Español] [Français] [Italiano]

  • Read more about the ASMQ project

Artemisinin-based combination treatments (ACTs) are considered to be the best treatments for uncomplicated P. falciparum malaria and are a key element of the global malaria control strategy.
Safe, rapid, and reliably effective, the combination of AS and MQ is one of four World Health Organization (WHO)-recommended ACTs as first-line antimalarial treatment since 2001.

ASMQ, the first new product for neglected diseases to be developed and registered in Brazil, is the second drug made available by the partners of DNDi’s FACT (Fixed-Dose ACT) Project. ASMQ is the fixed-dose formulation of the association of AS and MQ, which has been widely used in Latin America and Southeast Asia over the past decade.

Thanks to the collaboration between public partners in Brazil and Southeast Asia within DNDi’s FACT Project, this innovative fixed-dose formulation is now available in Brazil, where national control program authorities have found that the new fixed-dose ASMQ in programmatic use could have a significant impact in reducing reported malaria cases and malaria-related hospitalizations, as reported in preliminary results of a 1-year analysis of over 17,000 patients.1

”In 2006, the Brazilian Ministry of Health registered 145,000 cases of uncomplicated falciparum malaria, 99% of which were located in Legal Amazon. In 2007, we registered a reduction to 93,000 cases. Malaria-related hospital admissions also dropped from 9,500, in 2006, to approximately 6,000 in 2007. Basic health network expansion, early diagnosis, and the use of the new treatment – fixed-dose ASMQ – each played a critical role in obtaining such a positive impact,” said Dr. Gerson Penna, Brazil’s Health Surveillance Secretary in the Ministry of Health.

ASMQ, which combines 2 drugs (AS and MQ) into 1 small blue tablet, simplifies treatment for adults and children with a single daily dose of 1 or 2 tablets for 3 days, by reducing the number of tablets, and by ensuring that the combination of drugs are taken together and in the correct proportions. The needs of children, the primary victims of malaria worldwide, are addressed with ASMQ: 3 presentations of ASMQ are available for children; tablets are small and easily crushable.

Packaging is color-coded to easily identify the different dosage for each range and to allow for ease-of-use of patients and prescribers, and ASMQ is the first fixed-dose ACT to have a shelf-life of 3 years in tropical conditions.

According to Dr. Paolo Buss, Fiocruz President, the project has two main characteristics: “The role of Fiocruz is to develop knowledge, goods, products, and services that are of benefit to Brazilian society and its health system. In the specific case of ASMQ, not only did we reach this objective in collaboration with DNDi, but this Brazilian-developed product will also provide benefit to other countries. This drug will be used in Brazil, and in many other countries in Latin America and Southeast Asia.”

As a public good, ASMQ will be available at cost to the public sector of endemic countries at a target price of US$2.50 for the full adult treatment. This new treatment will be made available to children and adult patients throughout Latin America and Southeast Asia over the course of 2008 and 2009. Facilitated by DNDi, the principles of technology transfer have been agreed between Farmanguinhos and the Indian generic pharmaceutical company, Cipla, so that patients in Southeast Asia will have a local manufacturer.

According to Dr. Eduardo Costa, Chairman of Farmanguinhos/Fiocruz, “This project demonstrates that it is possible to develop innovative, needs-driven R&D technologies that will deliver new drugs. We were able to combine different facilities in many countries into a great public-private, intercontinental partnership. And now, we will transfer the technology of this product to a private laboratory in India (Cipla),” said Costa.

“This new fixed-dose combination is a public good that has been developed according to patients’ needs by being easy to use, more affordable and a quality product,” said Dr. Bernard Pecoul, Executive Director of DNDi. “The fact that ASMQ has been successfully developed, funded, and delivered by public partners in Brazil, Europe, and Southeast Asia as part of DNDi’s FACT Consortium shows an alternative way to develop drugs for neglected diseases.”

ASMQ is targeted as first-line treatment for children and adults suffering from uncomplicated P. falciparum malaria cases in Latin America and Asia. Every year, there are approximately 1 million cases of malaria in Latin America (25% of which are P. falciparum cases, and the majority of which are in Brazil), and approximately 3 million cases in Asia, where 30% of the global malaria-related mortality is found.

“This is good news for patients around the world as more affordable and easy-to-use fixed-dose treatment for malaria are needed,” Prof Nick White, Professor of Tropical Medicine at Oxford University. “With effective, safe, easier to use, and better tolerated treatments like this becoming available, it’s ever more urgent that we make sure these treatments reach the patients who actually need them.”

***

Malaria in Figures
• Malaria is a major cause of morbidity and mortality worldwide: malaria slows economic growth by 1.3% per year in endemic areas.
• The disease is present in over 100 countries and threatens half of the world’s population.
• Every year, 350 to 500 million cases of malaria occur worldwide, with over 1 million deaths.
• 99% of malaria cases in Brazil are found in the Amazonian basin, where the Brazilian national control program authorities have conducted the intervention study with ASMQ in programmatic use.

About Farmanguinhos/Fiocruz
A part of the Oswaldo Cruz Foundation (Fiocruz) of the Government of the Federative Republic of Brazil, Farmanguinhos/Fiocruz is one of the largest pharmaceutical laboratories in Brazil and has a long history of drug production in the field of neglected diseases, particularly for the treatment of AIDS.  Farmanguinhos/Fiocruz produces more than two billion pharmaceutical components per year, not just for AIDS but also for the treatment of endemic diseases such as malaria (ASMQ; primaquine and chloroquine), leprosy, tuberculosis, and filariasis. Farmanguinhos is located in the state of Rio de Janeiro. For further information, please consult www.far.fiocruz.br.

About DNDi
The Drugs for Neglected Diseases initiative (DNDi) is an independent, not-for-profit product development partnership working to research and develop new and improved treatments for neglected diseases such as malaria, leishmaniasis, human African trypanosomiasis, and Chagas disease. With the objective to address unmet patient needs for these diseases, DNDi was established in 2003 by Institut Pasteur and Médecins Sans Frontières along with four publicly-funded research organizations in neglected disease-endemic countries. Working in partnership with industry and academia, DNDi has the largest ever R&D portfolio for the kinetoplastid diseases and currently has 6 clinical and 4 preclinical projects. In 2007, DNDi delivered its first product, a fixed-dose antimalarial “ASAQ”, in partnership with sanofi-aventis; now in 2008, DNDi is delivering its second product, fixed-dose “ASMQ”.
For further information, please consult www.dndi.org.

The Fixed-Dose Artesunate-based Combination Therapies (FACT) Project, initiated in 2002, demonstrates the efficacy of public partnerships in the field of drug R&D for neglected diseases. Fast-track development, testing, and registration of the two fixed-dose combinations, artesunate-amodiaquine (ASAQ) and artesunate-mefloquine (ASMQ), were the primary objectives of the project and have been achieved.

The multi-partner FACT Project Consortium consists of DNDi; Farmanguinhos/Fiocruz, Brazil; Tropival of the Bordeaux II University, France; Oxford University, UK; Universiti Sains Malaysia; Mahidol University, Thailand; TDR in Switzerland; and the Centre National de Recherche et de Formation sur le Paludisme (CNRFP) in Burkina Faso. Consistent with DNDi’s mission of collaboration based on relative strengths, the FACT Project capitalizes on the skills and know-how of a broad range of partners in both developing and developed countries. Thus far, the FACT Project has received financial support from the European Union; Agence Française de Développement (AFD); the Dutch, the Spanish, and the UK governments; and MSF.


Media Enquiries


Farmanguinhos/Fiocruz

BRAZIL/LATIN AMERICA
Taís Motta
taismotta@far.fiocruz.br
+552133485123

Wagner de Oliveira
wagnerol@cict.fiocruz.br
+55218181 3589

DNDi
US/EUR/ASIA
Samantha Bolton
sbolton@dndi.org
+55 21 8253 2126; +41 79 239 2366

Ann-Marie Sevcsik
amsevcsik@dndi.org
+41 79 814 9147; 1-646-258-8131

BRAZIL/LATIN AMERICA
Sadia Kaenzig
skaenzig@dndi.org
+41 79 819 9971

Flavio Pontes
flavioguilhermepontes@gmail.com
+55 2181234133; +55 2122676599

Partnership Malaria

Read, watch, share

Loading...
Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

Healthcare workers looking into microscopes
Press releases
30 Nov 2022

Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

Journalists talking with healthcare workers
News
23 Nov 2022

DNDi media workshops – bringing together reporters and researchers to cover neglected disease research

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo